Safety of aztreonam in patients with cystic fibrosis and allergy to beta-lactam antibiotics

Rev Infect Dis. 1991 May-Jun:13 Suppl 7:S594-7. doi: 10.1093/clinids/13.supplement_7.s594.


In an open clinical trial, aztreonam was administered repeatedly to 15 cystic fibrosis patients who were chronically infected with Pseudomonas aeruginosa and had previously had severe hypersensitivity reactions to other beta-lactam antibiotics, including anaphylactic shock, generalized urticaria, and drug-associated fever. After negative results in a skin-prick test and a lack of reaction to an intravenous test dose of aztreonam, the patients were treated with aztreonam (150 mg/[kg.d]) in combination with tobramycin (10-20 mg/[kg.d]) for 14-day periods at 3- to 4-month intervals. To date, a total of 56 course of aztreonam have been administered to these patients (three to six courses per patient), and no type 1 hypersensitivity reactions have occurred. However, as a result of drug-associated fever, the administration of aztreonam had to be discontinued in two of 15 cases. The remaining 13 patients have tolerated treatment well.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents / adverse effects*
  • Aztreonam / adverse effects
  • Aztreonam / therapeutic use*
  • Child
  • Cystic Fibrosis / complications*
  • Drug Hypersensitivity*
  • Drug Therapy, Combination / therapeutic use
  • Female
  • Humans
  • Male
  • Prospective Studies
  • Pseudomonas Infections / complications
  • Pseudomonas Infections / drug therapy*
  • Tobramycin / therapeutic use


  • Anti-Bacterial Agents
  • Aztreonam
  • Tobramycin